索托维单抗用于新冠肺炎患者缺乏疗效：一项荟萃分析。 - Suppr

Suppr

超能文献

Lack of efficacy for sotrovimab use in patients with COVID-19: A meta-analysis.

作者信息

Ao Guangyu, Li Toni, Wang Yushu, Tran Carolyn, Qi Xin

机构信息

Department of Nephrology, Chengdu First People's Hospital, Chengdu, Sichuan, China.

School of Medicine, Queen's University, Kingston, Canada.

出版信息

J Infect. 2022 Jul;85(1):e10-e12. doi: 10.1016/j.jinf.2022.04.027. Epub 2022 Apr 21.

DOI:10.1016/j.jinf.2022.04.027

PMID:35461909

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9021041/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c61/9021041/7174a3375de8/gr1_lrg.jpg

相似文献

Lack of efficacy for sotrovimab use in patients with COVID-19: A meta-analysis.索托维单抗用于新冠肺炎患者缺乏疗效：一项荟萃分析。

J Infect. 2022 Jul;85(1):e10-e12. doi: 10.1016/j.jinf.2022.04.027. Epub 2022 Apr 21.

[Sotrovimab in controlling SARS-CoV-2 infection].[索托维单抗在控制新型冠状病毒2感染中的作用]

Pol Merkur Lekarski. 2022 Feb 22;50(295):48-50.

Sotrovimab lost neutralization efficacy against SARS-CoV-2 subvariants but remained clinically effective: Were monoclonal antibodies against COVID-19 rejected too early?索托维单抗对新冠病毒（SARS-CoV-2）变异株失去中和效力，但仍具有临床疗效：抗新冠单克隆抗体是否被过早摒弃？

J Infect Public Health. 2024 Sep;17(9):102512. doi: 10.1016/j.jiph.2024.102512. Epub 2024 Aug 7.

Efficacy of sotrovimab on omicron BA.2, BA.4 and BA.5 subvariants of sars-cov-2 vs. other early therapies: a systematic review and meta-analysis of literature data.在 SARS-CoV-2 的奥密克戎 BA.2、BA.4 和 BA.5 亚变种方面，索特罗维单抗对比其他早期疗法的疗效：文献数据的系统评价和荟萃分析。

Front Immunol. 2024 Jan 30;15:1295029. doi: 10.3389/fimmu.2024.1295029. eCollection 2024.

Outcome of very high-risk patients treated by Sotrovimab for mild-to-moderate COVID-19 Omicron, a prospective cohort study (the ANRS 0003S COCOPREV study).索托维单抗治疗轻至中度新冠病毒奥密克戎变异株感染的极高风险患者的结局：一项前瞻性队列研究（法国国家艾滋病研究机构0003S COCOPREV研究）

J Infect. 2022 Jun;84(6):e101-e104. doi: 10.1016/j.jinf.2022.04.010. Epub 2022 Apr 7.

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab.Sotrovimab 对 SARS-CoV-2 中和抗体用于治疗新型冠状病毒早期感染。

N Engl J Med. 2021 Nov 18;385(21):1941-1950. doi: 10.1056/NEJMoa2107934. Epub 2021 Oct 27.

Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.索特罗维单抗对伴有轻度至中度 COVID-19 的高危患者住院或死亡的影响：一项随机临床试验。

JAMA. 2022 Apr 5;327(13):1236-1246. doi: 10.1001/jama.2022.2832.

COVID-19 Updates: Monoclonal Antibodies for COVID-19.新冠疫情最新消息：用于治疗新冠的单克隆抗体

Med Lett Drugs Ther. 2022 Jan 24;64(1642):16.

Sotrovimab: First Approval.索托维单抗：首次批准。

Drugs. 2022 Mar;82(4):477-484. doi: 10.1007/s40265-022-01690-7.

Outcomes of bebtelovimab and sotrovimab treatment of solid organ transplant recipients with mild-to-moderate coronavirus disease 2019 during the Omicron epoch.贝特洛维单抗和索特罗维单抗治疗奥密克戎纪元中 COVID-19 轻症至中症的实体器官移植受者的结局。

Transpl Infect Dis. 2022 Aug;24(4):e13901. doi: 10.1111/tid.13901. Epub 2022 Jul 25.

引用本文的文献

Sotrovimab in the treatment of coronavirus disease-2019 (COVID-19): a systematic review and meta-analysis of randomized clinical trials.索特罗维单抗治疗 2019 冠状病毒病（COVID-19）：随机临床试验的系统评价和荟萃分析。

Naunyn Schmiedebergs Arch Pharmacol. 2024 Dec;397(12):9573-9589. doi: 10.1007/s00210-024-03298-y. Epub 2024 Jul 20.

Lessons we learned during the past four challenging years in the COVID-19 era: pharmacotherapy, long COVID complications, and vaccine development.我们在新冠疫情时代过去四年充满挑战的岁月中学到的经验教训：药物治疗、新冠长期并发症和疫苗研发。

Virol J. 2024 Apr 26;21(1):98. doi: 10.1186/s12985-024-02370-6.

The effect of bebtelovimab on clinical outcomes in patients with COVID-19: A meta-analysis.贝博泰洛维单抗对新冠病毒病患者临床结局的影响：一项荟萃分析。

J Infect. 2023 Jul;87(1):68-71. doi: 10.1016/j.jinf.2023.04.010. Epub 2023 Apr 19.

Efficacy and safety of sotrovimab in patients with COVID-19: A rapid review and meta-analysis.索特罗维单抗治疗 COVID-19 患者的疗效和安全性：快速综述和荟萃分析。

Rev Med Virol. 2022 Nov;32(6):e2402. doi: 10.1002/rmv.2402. Epub 2022 Oct 12.

The effect of SARS-CoV-2 double vaccination on the outcomes of hemodialysis patients with COVID-19: A meta-analysis.严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）双疫苗接种对新冠肺炎血液透析患者预后的影响：一项荟萃分析。

J Infect. 2023 Feb;86(2):e43-e45. doi: 10.1016/j.jinf.2022.09.022. Epub 2022 Sep 26.

SARS-CoV-2 Omicron BA.5: Riding the seventh wave in Central Canada.严重急性呼吸综合征冠状病毒2型奥密克戎BA.5：加拿大中部迎来第七波疫情

Influenza Other Respir Viruses. 2022 Nov;16(6):1202-1204. doi: 10.1111/irv.13046. Epub 2022 Aug 30.

Monoclonal antibody therapy improves severity and mortality of COVID-19 in organ transplant recipients: A meta-analysis.单克隆抗体疗法可改善器官移植受者新冠肺炎的严重程度和死亡率：一项荟萃分析。

J Infect. 2022 Oct;85(4):436-480. doi: 10.1016/j.jinf.2022.06.027. Epub 2022 Jul 1.

本文引用的文献

Effectiveness of Casirivimab-Imdevimab and Sotrovimab During a SARS-CoV-2 Delta Variant Surge: A Cohort Study and Randomized Comparative Effectiveness Trial.在 SARS-CoV-2 德尔塔变异株流行期间 Casirivimab-Imdevimab 和 Sotrovimab 的有效性：一项队列研究和随机对照有效性试验。

JAMA Netw Open. 2022 Jul 1;5(7):e2220957. doi: 10.1001/jamanetworkopen.2022.20957.

Real-World Use of Sotrovimab for Pre-Emptive Treatment in High-Risk Hospitalized COVID-19 Patients: An Observational Cross-Sectional Study.索托维单抗在高危住院COVID-19患者抢先治疗中的真实世界应用：一项观察性横断面研究。

Antibiotics (Basel). 2022 Mar 5;11(3):345. doi: 10.3390/antibiotics11030345.

Sotrovimab: First Approval.索托维单抗：首次批准。

Drugs. 2022 Mar;82(4):477-484. doi: 10.1007/s40265-022-01690-7.

JAMA. 2022 Apr 5;327(13):1236-1246. doi: 10.1001/jama.2022.2832.

Antibody evasion properties of SARS-CoV-2 Omicron sublineages.SARS-CoV-2 奥密克戎亚谱系的抗体逃逸特性。

Nature. 2022 Apr;604(7906):553-556. doi: 10.1038/s41586-022-04594-4. Epub 2022 Mar 3.

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.卡司瑞韦单抗和伊德韦单抗联合治疗住院 COVID-19 患者（RECOVERY）：一项随机、对照、开放标签、平台试验。

Lancet. 2022 Feb 12;399(10325):665-676. doi: 10.1016/S0140-6736(22)00163-5.

The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic.奥密克戎变异株对抗体介导的中和作用具有高度抗性：对控制 COVID-19 大流行的影响。

Cell. 2022 Feb 3;185(3):447-456.e11. doi: 10.1016/j.cell.2021.12.032. Epub 2021 Dec 24.

Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial.两种中和单克隆抗体疗法（索特罗维单抗和 BRII-196 加 BRII-198）治疗 COVID-19 住院成人的疗效和安全性（TICO）：一项随机对照试验。

Lancet Infect Dis. 2022 May;22(5):622-635. doi: 10.1016/S1473-3099(21)00751-9. Epub 2021 Dec 23.

Efficacy and safety of tocilizumab in hospitalized COVID-19 patients: A systematic review and meta-analysis.托珠单抗治疗住院COVID-19患者的疗效和安全性：一项系统评价和荟萃分析。

J Infect. 2022 Mar;84(3):418-467. doi: 10.1016/j.jinf.2021.11.013. Epub 2021 Nov 20.

Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis.针对 COVID-19 的抗体和细胞疗法：一项实时系统评价和网络荟萃分析。

BMJ. 2021 Sep 23;374:n2231. doi: 10.1136/bmj.n2231.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验